Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 4/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31362910 | 0.90 | TNF (0.37) | TNFGRM2HDAC3HDAC4HDAC1 | |
| SCHEMBL31362983 | 0.79 | TIPARP (0.42) | TIPARPTNFHDAC3HDAC1HDAC6 | |
| SCHEMBL31388970 | 0.77 | HTR2C (0.34) | GRM2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25319089 | 0.75 | TIPARP (0.39) | TIPARPTNFHDAC3HDAC1HDAC6 | |
| SCHEMBL30550904 | 0.75 | TIPARP (0.39) | TIPARPTNFHDAC3HDAC1HDAC6 | |
| SCHEMBL25319081 | 0.75 | TIPARP (0.39) | TIPARPTNFHDAC3HDAC1HDAC6 | |
| SCHEMBL31388996 | 0.75 | PSMB1 (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31362927 | 0.75 | HTR2C (0.32) | TBXAS1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25324896 | 0.72 | PSMB1 (0.41) | TIPARPTNFHDAC3HDAC1HDAC6 | |
| SCHEMBL2332782 | 0.72 | LMNA (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066328-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025024663-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066328-A1 | PARP7 INHIBITORS | PARP1, PARP2, PARP8 | TIPARP 524/4885TNF 4864/4885TBXAS1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.